{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T02:04:10Z","timestamp":1777946650329,"version":"3.51.4"},"reference-count":70,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2021,3,30]],"date-time":"2021-03-30T00:00:00Z","timestamp":1617062400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JMP"],"abstract":"<jats:p>Serous effusion cytology is widely employed in the initial evaluation of the etiology of effusions with a high diagnostic sensitivity. To standardize practices, The International System for Reporting Serous Fluid Cytology (TIS) was developed following best international practices, the most up-to-date literature, and expert consensus. In the context of this system, ancillary techniques play an important role. Besides defining basic principles in laboratory specimen handling, adequacy criteria, and a standardized reporting terminology with five diagnostic categories, TIS provides an actionable framework for using immunohistochemical and molecular testing in effusion samples, namely, in atypical, suspicious of malignant samples. For diagnostic purposes, these tests may be employed to distinguish between a primary and secondary neoplasm, to confirm a diagnosis of malignant mesothelioma vs. reactive mesothelial hyperplasia, and to correctly classify and determine the primary location of a metastasis. Theranostic molecular tests may also be used for these samples to evaluate potential therapeutic targets. Pathologists play a central role in guiding this process by determining adequacy and selecting appropriate ancillary tests. The activity in this area of research should increase in the near future as new therapeutic targets are discovered and new drugs enter the clinical practice.<\/jats:p>","DOI":"10.3390\/jmp2020007","type":"journal-article","created":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T00:13:10Z","timestamp":1617149590000},"page":"66-76","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["The International System for Reporting Serous Fluid Cytopathology: How to Incorporate Molecular Data in Cytopathology Reports"],"prefix":"10.3390","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8318-0945","authenticated-orcid":false,"given":"Daniel","family":"Pinto","sequence":"first","affiliation":[{"name":"Servi\u00e7o de Anatomia Patol\u00f3gica, Centro Hospitalar de Lisboa Ocidental, EPE, 1349-019 Lisboa, Portugal"},{"name":"NOVA Medical School, Universidade NOVA de Lisboa, 1169-056 Lisboa, Portugal"}]},{"given":"Ashish","family":"Chandra","sequence":"additional","affiliation":[{"name":"Cellular Pathology, Guy\u2019s and St. Thomas\u2019 NHS Foundation Trust, London SE1 9RT, UK"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1006-6946","authenticated-orcid":false,"given":"Fernando","family":"Schmitt","sequence":"additional","affiliation":[{"name":"IPATIMUP-Instituto de Patologia e Imunologia Molecular, Universidade do Porto, 4200-135 Porto, Portugal"},{"name":"Faculdade de Medicina, Universidade do Porto, 4200-319 Porto, Portugal"},{"name":"CINTESIS@RISE, 4200-450 Porto, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2021,3,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Marchevsky, A., Husain, A., and Galateau-Sall\u00e9, F. (2018). The Mesothelium. Practical Pathology of Serous Membranes, Cambridge University Press.","DOI":"10.1017\/9781316402009"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1002\/dc.24278","article-title":"Are we ready to develop a tiered scheme for the effusion cytology? A comprehensive review and analysis of the literature","volume":"47","author":"Farahani","year":"2019","journal-title":"Diagn. Cytopathol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies","volume":"61","author":"Altman","year":"2008","journal-title":"J. Clin. Epidemiol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1158\/1535-7163.MCT-16-0436","article-title":"Cell-Free DNA from Ascites and Pleural Effusions: Molecular Insights into Genomic Aberrations and Disease Biology","volume":"16","author":"Husain","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Faquin, W.C., Rossi, E.D., Baloch, Z., Barkan, G.A., Foschini, M.P., Kurtycz, D.F.I., Pusztaszeri, M., and Vielh, P. (2018). The Milan System for Reporting Salivary Gland Cytopathology, Springer.","DOI":"10.1007\/978-3-319-71285-7"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Rosenthal, D.L., Wojcik, E.M., and Kurtycz, D.F.I. (2015). The Paris System for Reporting Urinary Cytology, Springer.","DOI":"10.1007\/978-3-319-22864-8"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1159\/000499509","article-title":"The International Academy of Cytology Yokohama System for Reporting Breast Fine-Needle Aspiration Biopsy Cytopathology","volume":"63","author":"Field","year":"2019","journal-title":"Acta Cytol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Nayar, R., and Wilbur, D. (2015). The Bethesda System for Reporting Cervical Cytology: Definitions, Criteria, and Explanatory Notes, Springer.","DOI":"10.1007\/978-3-319-11074-5"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1089\/thy.2017.0500","article-title":"The 2017 Bethesda System for Reporting Thyroid Cytopathology","volume":"27","author":"Cibas","year":"2017","journal-title":"Thyroid Off. J. Am. Thyroid Assoc."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Pitman, M.B., and Layfield, L. (2015). The Papanicolaou Society of Cytopathology System for Reporting Pancreaticobiliary Cytology: Definitions, Criteria and Explanatory Notes, Springer International Publishing.","DOI":"10.1007\/978-3-319-16589-9"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1159\/000501536","article-title":"Announcement: The International System for Reporting Serous Fluid Cytopathology","volume":"63","author":"Chandra","year":"2019","journal-title":"Acta Cytol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.jasc.2019.08.006","article-title":"Proceedings of the American Society of Cytopathology Companion Session at the 2019 United States and Canadian Academy of Pathology Meeting Part 1: Towards an International System for Reporting Serous Fluid Cytopathology","volume":"8","author":"Crothers","year":"2019","journal-title":"J. Am. Soc. Cytopathol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.jasc.2020.05.015","article-title":"The international system for reporting serous fluid cytopathology-diagnostic categories and clinical management","volume":"9","author":"Pinto","year":"2020","journal-title":"J. Am. Soc. Cytopathol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/dc.24410","article-title":"Current applications of molecular testing on body cavity fluids","volume":"48","author":"Pinto","year":"2020","journal-title":"Diagn. Cytopathol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Lobo, C., Costa, J., Petronilho, S., Monteiro, P., Le\u00e7a, L., and Schmitt, F. (2020). Cytohistological correlation in serous effusions using the newly proposed International System for Reporting Serous Fluid Cytopathology: Experience of an oncological center. Diagn. Cytopathol.","DOI":"10.1002\/dc.24440"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1002\/cncy.21452","article-title":"A minimum fluid volume of 75 mL is needed to ensure adequacy in a pleural effusion: A retrospective analysis of 2540 cases","volume":"122","author":"Rooper","year":"2014","journal-title":"Cancer Cytopathol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1093\/ajcp\/aqv021","article-title":"A Minimum Volume of More Than 60 mL Is Necessary for Adequate Cytologic Diagnosis of Malignant Pericardial Effusions","volume":"145","author":"Rooper","year":"2016","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_18","first-page":"179","article-title":"An investigation of adequate volume for the diagnosis of malignancy in pleural fluids","volume":"22","author":"Thomas","year":"2011","journal-title":"Cytopathol. Off. J. Br. Soc. Clin. Cytol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1378\/chest.09-0641","article-title":"Prospective study to determine the volume of pleural fluid required to diagnose malignancy","volume":"137","author":"Swiderek","year":"2010","journal-title":"Chest"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1378\/chest.08-2002","article-title":"A prospective study of the volume of pleural fluid required for accurate diagnosis of malignant pleural effusion","volume":"135","author":"Abouzgheib","year":"2009","journal-title":"Chest"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1378\/chest.122.6.1913","article-title":"Volume of pleural fluid required for diagnosis of pleural malignancy","volume":"122","author":"Sallach","year":"2002","journal-title":"Chest"},{"key":"ref_22","first-page":"326","article-title":"Differentiation between malignant and non-malignant pleural effusion","volume":"67","author":"Pettersson","year":"1985","journal-title":"Eur. J. Respir. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/s41379-018-0138-z","article-title":"The utilization of cytologic and small biopsy samples for ancillary molecular testing","volume":"32","author":"Roh","year":"2019","journal-title":"Mod. Pathol."},{"key":"ref_24","first-page":"P3073","article-title":"Efficacy of cytology, cell blocks and thoracoscopic pleural biopsy in malignant pleural effusion diagnosis","volume":"42","author":"Altman","year":"2013","journal-title":"Eur. Respir. J."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"S276","DOI":"10.21037\/jtd.2017.10.88","article-title":"The pathological and molecular diagnosis of malignant pleural mesothelioma: A literature review","volume":"10","author":"Bruno","year":"2018","journal-title":"J. Thorac. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"214","DOI":"10.15585\/mmwr.mm6608a3","article-title":"Malignant Mesothelioma Mortality\u2014United States, 1999\u20132015","volume":"66","author":"Mazurek","year":"2017","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_27","unstructured":"Cibas, E., and Ducatman, B. (2020). Cytology: Diagnostic Principles and Clinical Correlates, Elsevier. [5th ed.]."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.legalmed.2007.06.001","article-title":"Accuracy and reproducibility of pleural effusion cytology","volume":"10","author":"Fassina","year":"2007","journal-title":"Leg. Med. Tokyo Jpn."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1002\/cncy.20087","article-title":"The Use of Immunohistochemistry to Distinguish Reactive Mesothelial Cells from Malignant Mesothelioma in Cytologic Effusions Reply","volume":"118","author":"Hasteh","year":"2010","journal-title":"Cancer Cytopathol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1534\/genetics.107.075739","article-title":"A genetic screen identifies novel polycomb group genes in Drosophila","volume":"176","author":"Fritsch","year":"2007","journal-title":"Genetics"},{"key":"ref_31","first-page":"565","article-title":"High Incidence of Somatic BAP1 Alterations in Sporadic Malignant Mesothelioma","volume":"10","author":"Nasu","year":"2015","journal-title":"J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/ng.855","article-title":"The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma","volume":"43","author":"Bott","year":"2011","journal-title":"Nat. Genet."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/j.1349-7006.2012.02223.x","article-title":"Frequent inactivation of the BAP1 gene in epithelioid-type malignant mesothelioma","volume":"103","author":"Yoshikawa","year":"2012","journal-title":"Cancer Sci."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/modpathol.2015.65","article-title":"BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations","volume":"28","author":"Cigognetti","year":"2015","journal-title":"Mod. Pathol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/cncy.21928","article-title":"A combination of MTAP and BAP1 immunohistochemistry in pleural effusion cytology for the diagnosis of mesothelioma","volume":"126","author":"Kinoshita","year":"2018","journal-title":"Cancer Cytopathol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.5858\/arpa.2018-0273-OA","article-title":"Utility of Methylthioadenosine Phosphorylase Compared with BAP1 Immunohistochemistry, and CDKN2A and NF2 Fluorescence In Situ Hybridization in Separating Reactive Mesothelial Proliferations From Epithelioid Malignant Mesotheliomas","volume":"142","author":"Berg","year":"2018","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.lungcan.2016.12.017","article-title":"Immunohistochemical detection of MTAP and BAP1 protein loss for mesothelioma diagnosis: Comparison with 9p21 FISH and BAP1 immunohistochemistry","volume":"104","author":"Hida","year":"2017","journal-title":"Lung Cancer Amst. Neth."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1002\/cncr.23413","article-title":"9p21 Deletion in the diagnosis of malignant mesothelioma in serous effusions additional to immunocytochemistry, DNA-ICM, and AgNOR analysis","volume":"114","author":"Onofre","year":"2008","journal-title":"Cancer"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1002\/cncy.21269","article-title":"Morphology of 9p21 homozygous deletion-positive pleural mesothelioma cells analyzed using fluorescence in situ hybridization and virtual microscope system in effusion cytology","volume":"121","author":"Ct","year":"2013","journal-title":"Cancer Cytopathol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/cncr.10923","article-title":"The use of CDKN2A deletion as a diagnostic marker for malignant mesothelioma in body cavity effusions","volume":"99","author":"Illei","year":"2003","journal-title":"Cancer"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1136\/jcp.2010.076794","article-title":"FISH assay development for the detection of p16\/CDKN2A deletion in malignant pleural mesothelioma","volume":"63","author":"Chung","year":"2010","journal-title":"J. Clin. Pathol."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Schmitt, F.C. (2018). Molecular Applications in Cytology, Springer International Publishing.","DOI":"10.1007\/978-3-319-74942-6"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"S95","DOI":"10.1016\/j.lungcan.2005.03.017","article-title":"Implications of P16\/CDKN2A deletion in pleural mesotheliomas","volume":"49","author":"Ladanyi","year":"2005","journal-title":"Lung Cancer Amst. Neth."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/dc.23491","article-title":"BAP1 Immunostain and CDKN2A (p16) FISH Analysis: Clinical Applicability for the Diagnosis of Malignant Mesothelioma in Effusions","volume":"44","author":"Walts","year":"2016","journal-title":"Diagn. Cytopathol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"5522","DOI":"10.21037\/jtd.2018.08.59","article-title":"Role of p16 deletion and BAP1 loss in the diagnosis of malignant mesothelioma","volume":"10","author":"Liu","year":"2018","journal-title":"J. Thorac. Dis."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/pin.12453","article-title":"BAP1 immunohistochemistry and p16 FISH results in combination provide higher confidence in malignant pleural mesothelioma diagnosis: ROC analysis of the two tests","volume":"66","author":"Hida","year":"2016","journal-title":"Pathol. Int."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1097\/PAS.0000000000000394","article-title":"BAP1 immunohistochemistry and p16 FISH to separate benign from malignant mesothelial proliferations","volume":"39","author":"Brandon","year":"2015","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_48","unstructured":"Bs, L.B., Bs, T.B., Pironi, F., Bs, S.S., Bs, R.B., Fabbri, E., Bs, G.D.C., and Rossi, G. (2020). The \u201cBrescia panel\u201d (Claudin-4 and BRCA-associated protein 1) in the differential diagnosis of mesotheliomas with epithelioid features versus metastatic carcinomas. Cancer Cytopathol."},{"key":"ref_49","first-page":"85","article-title":"The cytologic diagnosis of malignant neoplasms in pleural and peritoneal effusions","volume":"31","author":"Sears","year":"1987","journal-title":"Acta Cytol."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Corrin, B., and Nicholson, A.G. (2011). Chapter 13\u2014Pleura and chest wall. Pathology of the Lungs, Churchill Livingstone. [3rd ed.].","DOI":"10.1016\/B978-0-7020-3369-8.00013-6"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/00000478-200303000-00003","article-title":"CDX2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin: An immunohistochemical survey of 476 primary and metastatic carcinomas","volume":"27","author":"Werling","year":"2003","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Kristiansen, I., Stephan, C., Jung, K., Dietel, M., Rieger, A., Tolkach, Y., and Kristiansen, G. (2017). Sensitivity of HOXB13 as a Diagnostic Immunohistochemical Marker of Prostatic Origin in Prostate Cancer Metastases: Comparison to PSA, Prostein, Androgen Receptor, ERG, NKX3.1, PSAP, and PSMA. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18061151"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/PAS.0b013e3182a0218f","article-title":"GATA3: A multispecific but potentially useful marker in surgical pathology: A systematic analysis of 2500 epithelial and nonepithelial tumors","volume":"38","author":"Miettinen","year":"2014","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_54","first-page":"421","article-title":"Expression of immunohistochemical markers in primary and metastatic malignant melanoma: A comparative study in 70 patients using a tissue microarray technique","volume":"15","author":"Plaza","year":"2007","journal-title":"Appl. Immunohistochem. Mol. Morphol. AIMM"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/(SICI)1097-0142(19980425)84:2<71::AID-CNCR1>3.0.CO;2-G","article-title":"Cytologic features of sarcomas in fluids","volume":"84","author":"Abadi","year":"1998","journal-title":"Cancer Cytopathol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/modpathol.2016.230","article-title":"Claudin-4 expression distinguishes SWI\/SNF complex-deficient undifferentiated carcinomas from sarcomas","volume":"30","author":"Schaefer","year":"2017","journal-title":"Mod. Pathol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1002\/cncy.22197","article-title":"Clinical, cytologic, and immunohistochemical features of sarcomas involving body cavity fluids","volume":"127","author":"Chen","year":"2019","journal-title":"Cancer Cytopathol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1038\/modpathol.2013.179","article-title":"The role of cytogenetics and molecular diagnostics in the diagnosis of soft-tissue tumors","volume":"27","author":"Bridge","year":"2014","journal-title":"Mod. Pathol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/dc.20432","article-title":"Serous effusions in malignant lymphomas: A review","volume":"34","author":"Das","year":"2006","journal-title":"Diagn. Cytopathol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1200\/JCO.2017.76.7293","article-title":"Molecular Testing Guideline for the Selection of Patients with Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists\/International Association for the Study of Lung Cancer\/Association for Molecular Pathology Clinical Practice Guideline Update","volume":"36","author":"Kalemkerian","year":"2018","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.jasc.2019.07.005","article-title":"Proceedings of the American Society of Cytopathology companion session at the 2019 United States and Canadian Academy of Pathology Annual meeting, part 2: Effusion cytology with focus on theranostics and diagnosis of malignant mesothelioma","volume":"8","author":"Siddiqui","year":"2019","journal-title":"J. Am. Soc. Cytopathol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00428-019-02559-z","article-title":"Invited review\u2014Next-generation sequencing: A modern tool in cytopathology","volume":"475","author":"Pisapia","year":"2019","journal-title":"Virchows Arch."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.cell.2019.02.049","article-title":"A Tumor-Agnostic NTRK (TRK) Inhibitor","volume":"177","author":"Huang","year":"2019","journal-title":"Cell"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1002\/cncy.21899","article-title":"ALK and ROS1 testing on lung cancer cytologic samples: Perspectives","volume":"125","author":"Pisapia","year":"2017","journal-title":"Cancer Cytopathol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"11085","DOI":"10.1200\/jco.2013.31.15_suppl.11085","article-title":"The CAP-IASLC-AMP molecular testing guideline for the selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors","volume":"31","author":"Ladanyi","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_66","unstructured":"(2021, March 16). DNA Sequencing Costs: Data. Genome.gov, Available online: https:\/\/www.genome.gov\/about-genomics\/fact-sheets\/DNA-Sequencing-Costs-Data."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"a036798","DOI":"10.1101\/cshperspect.a036798","article-title":"Next-Generation Sequencing Technologies","volume":"9","author":"McCombie","year":"2019","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_68","first-page":"1122","article-title":"Are whole-exome and whole-genome sequencing approaches cost-effective? A systematic review of the literature","volume":"20","author":"Schwarze","year":"2018","journal-title":"Genet. Med. Off. J. Am. Coll. Med. Genet."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Horn, L. (2019). Pulmonary Adenocarcinoma: Approaches to Treatment, Elsevier.","DOI":"10.1016\/B978-0-323-55433-6.05001-X"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"46","DOI":"10.5858\/arpa.2019-0398-OA","article-title":"Evaluating Mismatch Repair\/Microsatellite Instability Status Using Cytology Effusion Specimens to Determine Eligibility for Immunotherapy","volume":"145","author":"Jacobi","year":"2021","journal-title":"Arch. Pathol. Lab. Med."}],"container-title":["Journal of Molecular Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2673-5261\/2\/2\/7\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T13:25:45Z","timestamp":1760361945000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2673-5261\/2\/2\/7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,30]]},"references-count":70,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,6]]}},"alternative-id":["jmp2020007"],"URL":"https:\/\/doi.org\/10.3390\/jmp2020007","relation":{},"ISSN":["2673-5261"],"issn-type":[{"value":"2673-5261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,30]]}}}